All In MedTech

Device Trial Radar · NCT04089059

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients (PROACTIVE- HF Trial)

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

738

Actual

Start

Jan 10, 2020

Primary completion

Apr 2028

Study completion Apr 2028

Sponsor

Lead sponsor
Endotronix, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 13, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

Conditions

  • Heart Failure NYHA Class III

Interventions

  • Cordella™ Pulmonary Artery Sensor SystemDevice

    The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation. 1. Cordella Sensor 2. Cordella Delivery System 3. myCordella Patient Reader 4. Reader Dock 5. Cordella Calibration Equipment (CalEQ) 6. myCordella Hub 7. Cordella Data Analysis Platform (CDAP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy 6 Month Incidence of HF Related Hospitalizations (HFH) or All-cause MortalityTime frame: 6 months
  2. Safety: Freedom From Device/System Related ComplicationTime frame: 6 months
  3. Safety: Freedom From Pressure Sensor FailureTime frame: 6 months

Locations

74 sites in 3 countries. Site status is shown where the registry gives one.

  • Ascension St Vincent's

    Birmingham, Alabama

  • Huntsville Hospital

    Huntsville, Alabama

  • Phoenix Cardiovascular Research Group/Insight

    Phoenix, Arizona

71 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.